Приверженность терапии больных с воспалительными заболеваниями кишечника


Цитировать

Полный текст

Аннотация

Воспалительные заболевания кишечника относятся к аутоиммунным системным формам патологии. Концепция постоянного пожизненного приема лекарственных препаратов является краеугольным камнем в их терапии. В обзоре представлены факторы, снижающие приверженность больных лечению и пути ее повышения. Они включают информирование пациента о заболевании и лечении, подбор индивидуального режима терапии, закрепление достигнутого, обеспечение социальной поддержки и взаимодействие с другими специалистами.

Об авторах

Асфольд Иванович Парфенов

ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы

Email: asfold@mail.ru
д.м.н., проф., зав. отд. патологии кишечника Москва, Россия

Анна Валерьевна Каграманова

ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы

к.м.н., с.н.с. отд-ния воспалительных заболеваний кишечника Москва, Россия

Анаит Фахрадовна Бабаян

ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы

врач-гастроэнтеролог отд-ния воспалительных заболеваний кишечника Москва, Россия

Олег Владимирович Князев

ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы

д.м.н., зав. отд-нием воспалительных заболеваний кишечника Москва, Россия

Список литературы

  1. Chan W, Chen A, Tiao D, Selinger C, Leong R. Medication adherence in inflammatory bowel disease. Intest Res. 2017 Oct;15(4):434-45. doi: 10.5217/ir.2017.15.4.434. Epub 2017 Oct 23. Review.
  2. Cramer J.A, Roy A, Burrell A, Fairchild C.J, Fuldeore M.J, Ollendorf D.A, Wong P.K. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-7.
  3. Sackett D.L, Haynes R.B. Compliance with therapeutic regimens. Baltimore: The Johns Hopkins University Press; 1976.
  4. Vrijens B, De Geest S, Hughes D.A, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73:691-705. doi: 10.1111/j.1365-2125.2012.04167.x
  5. Jackson C.A, Clatworthy J, Robinson A, Horne R. Factors associated with non - adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2010;105:525-39. doi: 10.1038/ajg.2009.685
  6. Kawakami A, Tanaka M, Nishigaki M, et al. Relationship between non - adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. J Gastroenterol. 2013;48:1006-15. doi: 10.1007/s00535-012-0721-x
  7. Kim S.B, Kim K.O, Jang B.I, et al. Patients’ beliefs and attitudes about their treatment for inflammatory bowel disease in Korea. J Gastroenterol Hepatol. 2016;31:575-80. doi: 10.1111/jgh.13155
  8. Spekhorst L.M, Hummel T.Z, Benninga M.A, van Rheenen P.F, Kindermann A. Adherence to oral maintenance treatment in adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2016;62:264-70. doi: 10.1097/MPG.0000000000000924
  9. Jeganathan J, Lee C.H, Rahme A, et al. Medication adherence in transitional inflammatory bowel disease patients: a multicenter pilot study. J Gastroenterol Hepatol. 2014;29:111.
  10. Selinger C, Robinson A, Leong R. Non - adherence to inflammatory bowel disease maintenance medication: extent and predictors. J Gastroenterol Hepatol. 2011;26:116.
  11. Lopez A, Billioud V, Peyrin-Biroulet C, Peyrin-Biroulet L. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis. 2013;19:1528-33. doi: 10.1097/MIB.0b013e31828132cb
  12. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39-43.
  13. Khan N, Abbas A.M, Bazzano L.A, Koleva Y.N, Krousel-Wood M. Long - term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system. Aliment Pharmacol Ther. 2012;36:755-64. doi: 10.1111/apt.12013
  14. Van der Have M, Oldenburg B, Kaptein A.A, et al. Non - adherence to anti-TNF therapy is associated with illness perceptions and clinical outcomes in outpatients with inflammatory bowel disease: results from a prospective multicentre study. J Crohns Colitis. 2016;10:549-55. doi: 10.1093/ecco-jcc/jjw002
  15. Kane S, Shaya F. Medication non - adherence is associated with increased medical health care costs. Dig Dis Sci. 2008;53:1020-4. doi: 10.1007/s10620-007-9968-0
  16. Hommel K.A, Davis C.M, Baldassano R.N. Medication adherence and quality of life in pediatric inflammatory bowel disease. J Pediatr Psychol. 2008;33:867-74. doi: 10.1093/jpepsy/jsn022
  17. Horváth G, Farkas K, Hollósi R, et al. Is there any association between impaired health - related quality of life and non - adherence to medical therapy in inflammatory bowel disease? Scand J Gastroenterol. 2012;47:1298-303. doi: 10.3109/00365521.2012.703233
  18. Perry J, Chen A, Kariyawasam V, Choong C, Teh W.L, Mitrev N, Kohler F, Leong R.W.L. Medication non - adherence in inflammatory bowel diseases is associated with disability. Intest Res. 2018 Oct;16(4):571-8. doi: 10.5217/ir.2018.00033
  19. Robinson A, Hankins M, Wiseman G, Jones M. Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse. Aliment Pharmacol Ther. 2013;38:531-8. doi: 10.1111/apt.12396
  20. Cramer J.A, Scheyer R.D, Mattson R.H. Compliance declines between clinic visits. Arch Intern Med. 1990;150:1509-10.
  21. Fong S, Ward M.G, Nasr I, et al. PWE-111 higher red blood cell methotrexate polyglutamates correlate with increased disease activity, and are useful in assessing adherence. Gut. 2014;63(Suppl 1):A173.
  22. Gifford A.E, Berg A.H, Lahiff C, Cheifetz A.S, Horowitz G, Moss A.C. A random urine test can identify patients at risk of mesalamine non - adherence: a prospective study. Am J Gastroenterol. 2013;108:249-55. doi: 10.1038/ajg.2012.419
  23. Andrade S.E, Kahler K.H, Frech F, Chan K.A. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565-74. doi: 10.1002/pds.1230
  24. Nguyen T.M, La Caze A, Cottrell N. What are validated selfreport adherence scales really measuring? A systematic review. Br J Clin Pharmacol. 2014;77:427-45. doi: 10.1111/bcp.12194
  25. Morisky D.E, Di Matteo M.R. Improving the measurement of selfreported medication nonadherence: final response. J Clin Epidemiol. 2011;64:262-3.
  26. Trindade A.J, Ehrlich A, Kornbluth A, Ullman T.A. Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. Inflamm Bowel Dis. 2011;17:599-604. doi: 10.1002/ibd.21310
  27. Kane S, Becker B, Harmsen W.S, Kurian A, Morisky D.E, Zinsmeister A.R. Use of a screening tool to determine nonadherent behavior in inflammatory bowel disease. Am J Gastroenterol. 2012;107:154-60. doi: 10.1038/ajg.2011.317
  28. Selinger C.P, Eaden J, Jones D.B, et al. Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2199-206. doi: 10.1097/MIB.0b013e31829ed8a6
  29. Moss A.C, Lillis Y, Edwards George J.B, et al. Attitudes to mesalamine questionnaire: a novel tool to predict mesalamine nonadherence in patients with IBD. Am J Gastroenterol. 2014;109:1850-5. doi: 10.1038/ajg.2014.158
  30. Waters B.M, Jensen L, Fedorak R.N. Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial. Can J Gastroenterol. 2005;19:235-44.
  31. Tiao D.K, Jeganathan J, Chen A., et al. Impact of targeted pharmacist counselling intervention on IBD medication adherence. J Gastroenterol Hepatol. 2014;29:106.
  32. Kripalani S, Yao X, Haynes R.B. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167:540-50. doi: 10.1001/archinte.167.6.540
  33. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol. 2003;1:170-3.
  34. Dignass A.U, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:762-9.
  35. Suzuki Y, Iida M, Ito H, et al. 2.4 g Mesalamine (Asacol 400 mg tablet) once daily is as effective as three times daily in maintenance of remission in ulcerative colitis: a randomized, noninferiority, multi - center trial. Inflamm Bowel Dis. 2017;23:822-32. doi: 10.1097/MIB.0000000000001065
  36. Fenerty S.D, West C, Davis S.A, Kaplan S.G, Feldman S.R. The effect of reminder systems on patients’ adherence to treatment. Patient Prefer Adherence. 2012;6:127-35. doi: 10.2147/PPA.S26314
  37. Greenley R.N, Gumidyala A.P, Nguyen E, et al. Can you teach a teen new tricks? Problem solving skills training improves oral medication adherence in pediatric patients with inflammatory bowel disease participating in a randomized trial. Inflamm Bowel Dis. 2015;21:2649-57. doi: 10.1097/MIB.0000000000000530
  38. Cook P.F, Emiliozzi S, El-Hajj D, Mc Cabe M.M. Telephone nurse counseling for medication adherence in ulcerative colitis: a preliminary study. Patient Educ Couns. 2010;81:182-6. doi: 10.1016/j.pec.2009.12.010
  39. Elkjaer M, Shuhaibar M, Burisch J, et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web - guided ‘Constant - care’ approach. Gut. 2010;59:1652-61. doi: 10.1136/gut.2010.220160
  40. Moshkovska T, Stone M.A, Smith R.M, Bankart J, Baker R, Mayberry J.F. Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: results from an exploratory randomized controlled trial. Inflamm Bowel Dis. 2011;17:1874-81. doi: 10.1002/ibd.21570
  41. Hommel K.A, Herzer M, Ingerski L.M, Hente E, Denson L.A. Individually tailored treatment of medication nonadherence. J Pediatr Gastroenterol Nutr. 2011;53:435-9. doi: 10.1097/MPG.0b013e3182203a91
  42. Hommel K.A, Hente E.A, Odell S, et al. Evaluation of a groupbased behavioral intervention to promote adherence in adolescents with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2012;24:64-9. doi: 10.1097/MEG.0b013e32834d09f1
  43. Aguas Peris M, Del Hoyo J, Bebia P, et al. Telemedicine in inflammatory bowel disease: opportunities and approaches. Inflamm Bowel Dis. 2015;21:392-9. doi: 10.1097/MIB.0000000000000241
  44. Pedersen N, Thielsen P, Martinsen L, et al. eHealth: individualization of mesalazine treatment through a self - managed webbased solution in mild - to - moderate ulcerative colitis. Inflamm Bowel Dis. 2014;20:2276-85. doi: 10.1097/MIB.0000000000000199
  45. Cross R.K, Cheevers N, Rustgi A, Langenberg P, Finkelstein J. Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflamm Bowel Dis. 2012;18:1018-25. doi: 10.1002/ibd.21795
  46. Hommel K.A, Hente E, Herzer M, Ingerski L.M, Denson L.A. Telehealth behavioral treatment for medication nonadherence: a pilot and feasibility study. Eur J Gastroenterol Hepatol. 2013;25:469-73. doi: 10.1097/MEG.0b013e32835c2a1b

© ООО "Консилиум Медикум", 2018

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах